Sun Pharmaceuticals Industries has received approval from USFDA, for its psoriasis drug Ilumya. Ilumya is generically known as tildrakizumab-asmn and comes under specialty drugs –...
EquityPanditβs Outlook forΒ Sun Pharma for the weekΒ Β (Mar 12, 2018Β βΒ Mar 16, 2018) :Β SUN PHARMA: SUN PHARMA closed the week on negative note losing...
EquityPanditβs Outlook forΒ Sun Pharma for the weekΒ Β (Mar 05, 2018Β βΒ Mar 09, 2018) :Β SUN PHARMA: SUN PHARMA closed the week on negative note losing...
EquityPanditβs Outlook for Sun PharmaΒ for the weekΒ Β (Feb 26, 2018Β βΒ Mar 02, 2018) :Β SUN PHARMA: SUN PHARMA closed the week on negative note losing...
EquityPanditβs Outlook for Sun PharmaΒ for the weekΒ Β (Feb 19, 2018Β βΒ Feb 23, 2018) :Β SUN PHARMA: SUN PHARMA closed the week on negative note losing...
Sun Pharma has reported 75.2% decline in the profit for the quarter ended December 31,2017, at Rs.365.4 crore. Profit for the corresponding quarter in the...
EquityPanditβs Outlook for Sun PharmaΒ for the weekΒ Β (Feb 12, 2018Β βΒ Feb 16, 2018) :Β SUN PHARMA: SUN PHARMA closed the week on positive note gaining...
EquityPanditβs Outlook for Sun PharmaΒ for the weekΒ Β (Feb 05, 2018Β βΒ Feb 09, 2018) :Β SUN PHARMA: SUN PHARMA closed the week on negative note losing...
EquityPanditβs Outlook for Sun PharmaΒ for the weekΒ Β (Jan 29, 2018Β βΒ Feb 02, 2018) :Β SUN PHARMA: SUN PHARMA closed the week on positive note gaining...
EquityPanditβs Outlook for Sun PharmaΒ for the weekΒ Β (Jan 22, 2018Β βΒ Jan 25, 2018) :Β SUN PHARMA: SUN PHARMA closed the week on negative note losing...